RE:RE:RE:Nice BreakoutWell, just look at what the Nasdaq listing might do to our share price versus that hardly known CSE.
Lets take DGII on the Nasdaq which is an excellent proxy for DCSI (.
https://stockhouse.com/companies/bullboard?symbol=c.dcsi&postid=34913913 )
DGII trades at a market cap of $1,25 Billion US on annual sales of about $400 million ( $282 million in the first 9 months of 2022 ).
So, about 3 times annual revenues .
DCSI had sales of $ 13. 6 million US for the first 6 months of 2022.
Ignoring any growth for the second half of 2022: we have about $27 million US which is about $35 million CAD.
So, 3 times $35 m is $105 million , which equates to about $6 CAD per share had we been listed on the Nasdaq instead of CSE.
It won't come right away, but with ongoing and new promotions, an easy double from here seems reasonable while we wait.
Everything looks good for growth in the second half of 2022 and going forward and the Nasdaq listing seems a certainty
So, the near term upside here is very substantial just from a listing on the Nasdaq